Streetwise Biotech / Pharmaceuticals Articles



Micro-Cap Pharma Moving Ahead with Plans for Phase 3 US Trial of a Repurposed Drug for Covid-19
Source: Streetwise Reports  (6/3/20)
Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations. More >


Immunotherapy Firm Releases Data Showing Treatment Potential Against Sepsis
Source: Streetwise Reports  (6/3/20)
Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report. More >


Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data
Source: Streetwise Reports  (6/3/20)
Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease. More >


Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug
Source: Streetwise Reports  (6/1/20)
Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. More >


Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19
Source: Streetwise Reports  (5/27/20)
Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil. More >


Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'
Source: Streetwise Reports  (5/27/20)
Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. More >


Biotech Identifies Antibody with 100% SARS-CoV-2 Inhibition
Source: Streetwise Reports  (5/27/20)
The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report. More >


Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data
Source: Streetwise Reports  (5/27/20)
Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. More >


Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial
Source: Streetwise Reports  (5/26/20)
Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373. More >


Peter Epstein

Vertically Integrated Hemp/CBD Player Sweet Earth Holdings Debuts on CSE
Source: Peter Epstein for Streetwise Reports  (5/26/20)
With CBD showing some promise against Covid-19 and cannabis stocks rising, Peter Epstein of Epstein Research discusses the market with Sweet Earth Holdings executives. More >


Surface Oncology Shares Trade Up 40% on Phase 1 Study Plans for SRF617 Combined with Merck's KEYTRUDA
Source: Streetwise Reports  (5/20/20)
Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. More >


US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis
Source: Streetwise Reports  (5/20/20)
Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. More >


Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results
Source: Streetwise Reports  (5/19/20)
Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. More >


Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data
Source: Streetwise Reports  (5/18/20)
Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. More >


Biopharma Seeks Ethics Approval in Australia to Test COVID-19 Treatment
Source: Streetwise Reports  (5/18/20)
Algernon Pharmaceuticals intends to test a repurposed drug for this indication, in a trial in three countries. More >


Cannabis Cultivator Shifts Focus to Commercializing Technology
Source: Streetwise Reports  (5/18/20)
Sproutly Canada has received capital investment from Infusion Biosciences. More >


Biotech Expands Antibody Research Across Multiple Neurodegenerative Diseases and Covid-19
Source: Streetwise Reports  (5/14/20)
ProMIS Neurosciences advances its various antibody programs related to neurodegenerative diseases and viral infections such as Covid-19. More >


Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data
Source: Streetwise Reports  (5/14/20)
Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. More >


Acceleration of COVID-19 Vaccine Programs Could Benefit U.S. Biotech
Source: Streetwise Reports  (5/13/20)
The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report. More >


MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results
Source: Streetwise Reports  (5/11/20)
Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. More >


Pharmaceutical Firm Gains Ethics Approval for Phase 2 Human IPF and Chronic Cough Trial
Source: Streetwise Reports  (5/10/20)
Algernon Pharmaceuticals reported that it has received ethics approval in Australia for a Phase 2 human clinical study of NP-120 (Ifenprodil) for use in treatment of idiopathic pulmonary fibrosis and chronic cough. More >


Protagonist's Shares Nearly Double After Reporting Q1 Earnings and Positive Phase 2 Trial Results
Source: Streetwise Reports  (5/8/20)
Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer. More >


Building a Better Covid-19 Antibody Test
Source: Streetwise Reports  (5/6/20)
ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. More >


California Biotech Partners for Manufacture of COVID-19 Vaccine Candidate
Source: Streetwise Reports  (5/6/20)
Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report. More >


Biotech Develops Antagonists for Protein Tied to Neurodegenerative Diseases
Source: Streetwise Reports  (5/6/20)
ProMIS Neurosciences' antagonists prevent dysfunctional protein aggregation. More >


Showing Results: 1 to 25 of 1148 Next

Notable Quotes

"We remain bullish on MAG."
– Richard Gray, Cormark Securities

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"Underground development at MAG's Juanicipio has reached 27 km."
– Heiko Ihle, H.C. Wainwright & Co., Rodman & Renshaw